Loading…
Loading…
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for CRT and 80,000+ other tickers.
See exactly how CRT's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for CRT and 80,000+ other tickers.
Cross Timbers Royalty Trust functions as an express trust within the United States, holding substantial stakes in various energy-related assets. The trust maintains a 90% net profits interest across a selection of producing and nonproducing royalty and overriding royalty properties located in Texas, Oklahoma, and New Mexico. Additionally, it secures a 75% net profits working interest in seven specific properties, four of which are situated in Texas and three in Oklahoma. This entity was established in 1991 and its corporate headquarters are based in Dallas, Texas.
DALLAS, July 21, 2026 /PRNewswire/ -- Argent Trust Company, as Trustee of the Cross Timbers Royalty Trust (the "Trust") (NYSE: CRT), today declared a cash distribution to the holders of its units of beneficial interest of $0.061397 per unit, payable on August 14, 2026, to unitholders of record on July 31, 2026. The following table shows underlying oil and gas sales and average prices attributable to the current month and prior month distributions.
REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Speciali
DALLAS, June 18, 2026 /PRNewswire/ -- Argent Trust Company, as Trustee of the Cross Timbers Royalty Trust (the "Trust") (NYSE: CRT), today declared a cash distribution to the holders of its units of beneficial interest of $0.044186 per unit, payable on July 15, 2026, to unitholders of record on June 30, 2026. The following table shows underlying oil and gas sales and average prices attributable to the current month and prior month distributions.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that calderasib (MK-1084), an investigational oral specific KRAS G12C inhibi
AstraZeneca's IMFINZIÂ (durvalumab) in combination with Bacillus Calmette-GuÃrin (BCG) induction and maintenance therapy has been approved in the US for the